Projekt

A phase 3 multicenter, randomized, prospective, open-label trial of ibrutinibmonotherapy versus fixed-duration venetoclax plus obinutuzumab versusfixed-duration ibrutinib plus venetoclax in patients with previously untreatedchronic lymphocytic leukemia (CLL)

Laufend - Rekrutierung – beendet · 2021 bis 2099

Baumann Michael, Harder Anja, Quinter Janine